Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial-Reference-Cited by-同舟云学术

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial

Published:2023-09 Issue:9 Volume:18 Page:1209-1221
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

John Thomas,Grohé Christian,Goldman Jonathan W.,Shepherd Frances A.,de Marinis Filippo,Kato Terufumi,Wang Qun,Su Wu-Chou,Choi Jin Hyuk,Sriuranpong Virote,Melotti Barbara,Fidler Mary J.,Chen Jun,Albayaty Muna,Stachowiak Marta,Taggart Sarah,Wu Yi-Long,Tsuboi Masahiro,Herbst Roy S.,Majem Margarita

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014

2. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017

3. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

4. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer;Reungwetwattana;J Clin Oncol,2018

5. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3);Wu;J Clin Oncol,2018

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies;Cancers;2024-08-06

2. New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors;American Society of Clinical Oncology Educational Book;2024-06

3. Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer;Chinese Clinical Oncology;2024-04

4. Combinatorial Therapies: Embracing Our Multifaceted Future;International Journal of Radiation Oncology*Biology*Physics;2024-04

5. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review;Lung Cancer;2024-01